借力推动前列腺癌 CAR-T 细胞治疗进展
Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.
P-PSMA-101 是一款首创的、富集干细胞记忆 T 细胞的、靶向前列腺特异性膜抗原（PSMA）的嵌合抗原受体（CAR）T 疗法。
94.4分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
STEAP1：前列腺癌治疗中的潜力靶点
英文原题：STEAP1: a promising target in prostate cancer therapy.
查看英文原题
STEAP1: a promising target in prostate cancer therapy.
研究概要
STEAP1（六次跨膜前列腺上皮抗原 1）是一种在 >85% 的前列腺肿瘤中高表达、而在正常组织中几乎不表达的细胞表面蛋白，使其成为靶向治疗的有前景候选靶点。
中文摘要
前列腺癌（PCa）发生转移后大多仍无法治愈，治疗需求尚未得到满足，因此亟需开发新疗法。STEAP1（前列腺六跨膜上皮抗原 1）是一种细胞表面蛋白，在超过 85% 的前列腺肿瘤中高表达，而在正常组织中几乎不表达或完全不表达，因此有望成为靶向治疗的目标。本文总结并讨论了 STEAP1 在前列腺癌治疗中的潜力及相关最新发现。
展开英文摘要原文
The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.
论文信息
- 作者
- Singh R、Kyte JA
- 第一作者单位
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway.Norway
- 通讯作者单位
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway; Department of Clinical Cancer Research, Oslo University Hospital Radiumhospitalet, 0424 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway; Faculty of Health Sciences, Oslo Metropolitan University, 0166 Oslo, Norway. Electronic address: jonky@ous-hf.no.Norway
- 文献类型
- 综述
- 期刊
- Trends in cancer2025 Aug
- 原文标识
- PubMed 40527692 · DOI 10.1016/j.trecan.2025.05.007